Economic impact of heart failure with preserved ejection fraction: insights from the ALDO‐DHF trial
Abstract Aims Although heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause for hospitalization, its overall costs remain unclear. Therefore, we assessed the health care‐related costs of ambulatory HFpEF patients and the effect of spironolactone. Methods and results The ald...
Main Authors: | Djawid Hashemi, Ludwig Dettmann, Tobias D. Trippel, Volker Holzendorf, Johannes Petutschnigg, Rolf Wachter, Gerd Hasenfuß, Burkert Pieske, Antonia Zapf, Frank Edelmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-06-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.12606 |
Similar Items
-
Ökonomische Relevanz von Herzinsuffizienz mit erhaltener Ejektionsfraktion und der Einfluss einer Therapie mit Spironolacton. Ergebnisse der prospektiven, randomisierten und placebo- kontrollierten ALDO-DHF-Studie
by: Dettmann, Ludwig
Published: (2018) -
Heterogeneous Metabolic Response to Exercise Training in Heart Failure with Preserved Ejection Fraction
by: Martin Bahls, et al.
Published: (2019-04-01) -
Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides
by: Kaiyuan Zhu, et al.
Published: (2021-07-01) -
Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fraction
by: Anna Bobenko, et al.
Published: (2020-06-01) -
The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study
by: Tobias Daniel Trippel, et al.
Published: (2021-04-01)